Sermorelin protocol

Check your units. The units in this table assume 2 mg/mL or 4 mg/mL, but the guide's recommended mix makes 5 mg/mL. If you mix it that way, your units will be different. Use the calculator to get the right draw for your vial.

Standard

Weeks 1–2

10u (2 mg/mL); 5.0u (4 mg/mL)

200 mcg · Nightly 5×/week

Start low; assess sleep and tolerance before increasing.

Weeks 3–12

15u (2 mg/mL); 7.5u (4 mg/mL)

300 mcg · Nightly 5×/week

Standard effective dose. Often paired with a GHRP for a larger combined pulse.

Off

4 weeks

Let the pituitary and receptors recover before the next cycle.

Phase	How often	Dose	Units	Notes
Weeks 1–2	Nightly 5×/week	200 mcg	10u (2 mg/mL); 5.0u (4 mg/mL)	Start low; assess sleep and tolerance before increasing.
Weeks 3–12	Nightly 5×/week	300 mcg	15u (2 mg/mL); 7.5u (4 mg/mL)	Standard effective dose. Often paired with a GHRP for a larger combined pulse.
Off	4 weeks	–	–	Let the pituitary and receptors recover before the next cycle.

Units columns in the source are given at 2 mg/mL and 4 mg/mL.

Cycle & timing

Cycle: 8–12 weeks on / 4 weeks off.

Timing: Fasted pre-bed (largest natural GH pulse is during deep sleep). No food 60–90 min before / 60 min after, carbs and fats blunt the pulse.

Where: SubQ, abdomen preferred. Rotate.

What to expect

Deeper sleep within 1–2 weeks; recovery and body-composition changes over 8–12 weeks. Gentler and more physiological than injected HGH.

How much to buy

For 12-wk @ 300 mcg × 5/wk:

9

× 2mg vials

4

× 5mg vials

2

× 10mg vials

Men & women

Men: Men convert GH to IGF-1 more efficiently and more often overshoot the age ceiling (a higher malignancy signal), aim mid-normal for age, don’t chase the top.

Women: Women make ~3× the GH of men yet have similar IGF-1, they’re less responsive, so often need a higher dose to move IGF-1. Oral estrogen blunts IGF-1 further (read it as running low); a skin patch/gel is more predictable.

Dilution calculator

Set to the guide's typical mix for Sermorelin. Change anything to see where to draw.

Vial size

BAC water added

Dose you want

Draw to

6u

Volume

0.06 mL

Strength

5 mg/mL

Doses per vial

16

Assumes a U-100 insulin syringe (100 units = 1 mL). Double-check against the compound's page before you draw.

Recommended mixes

Vial	Water	Strength
2 mg	0.4 mL	5 mg/mL
5 mg	1 mL	5 mg/mL
10 mg	2 mL	5 mg/mL

2 mg: 1 unit = 0.05 mg (50 mcg)

Storage

PowderFreeze-dried: -4°F.
MixedReconstituted: 36–46°F, up to 4–6 weeks.

Don't use if: Active malignancy of any kind (GH/IGF-1 can promote tumor growth) · Severe diabetic retinopathy · Acute critical illness (per somatropin label, applies to GH-axis stimulators) · Pregnancy and lactation

Stop if you notice

Fasting glucose rises >20 mg/dL above baseline
IGF-1 rises above the upper limit of normal for age
New persistent joint pain or carpal tunnel symptoms
New skin changes or enlarging moles; vision changes

Side effects

Injection-site flushing/warmth, occasional headache, mild water retention. Self-limiting feedback makes overshoot uncommon.

Drug interactions

Glucocorticoids: blunt GH response, minimize or time away from injection. Insulin / antidiabetics: GH worsens insulin resistance, expect dose adjustments + tighter monitoring. Levothyroxine: GH lowers free T4, recheck TSH/fT4 quarterly. Oral estrogens: blunt GH-stimulated IGF-1; transdermal doesn’t.

Labs

IGF-1 (baseline + Week 8 + end). Target upper-normal for age. Fasting glucose and HbA1c (baseline + end of cycle). Age-appropriate cancer screening before starting. Out of range? IGF-1 above your age range = too much growth signal (feeds hidden cancer, enlarges organs) → drop the dose; rising glucose/HbA1c = sugar creeping up.

What these labs mean →

Warnings

Insulin resistance / worsening glycemic control with sustained use. Fluid retention, peripheral edema, carpal tunnel with extended use. Joint and muscle pain. IGF-1 elevation: theoretical malignancy promotion if pushed beyond physiological ranges. More self-limiting than direct HGH (feedback-regulated), but class warnings still apply.

Patient education

You are stimulating your own GH, not replacing it; effects build gradually. Most GH is released in deep sleep, dose pre-bed and protect sleep. Food within 90 min blunts the pulse, fasted is standard. Not for use during active malignancy or pregnancy; report new lumps or vision changes.

These apply on top of the universal safety rules.

Pairs well with

Ipamorelin

canonical GHRH + GHRP pulse synergy

Ipamorelin

CJC-1295 (No DAC)

Wolverine Blend (BPC-157 + TB-500)

recovery

Wolverine Blend

Avoid with

Active malignancy

Severe insulin resistance

Combining multiple GHRH analogs at once

Can Sermorelin + Ipamorelin share a syringe?

Mix freely: the classic GH pair. One GHRH primes the pituitary and one GHRP triggers a bigger pulse. Same solvent, pre-bed, empty stomach.

What it does

Was FDA-approved as Geref for pediatric GH deficiency / GH-axis testing (discontinued 2008); now compounded off-label for adults.

Sermorelin is GHRH(1–29), the active fragment of growth-hormone-releasing hormone. It binds pituitary GHRH receptors and triggers a physiological GH pulse that is still regulated by your own feedback loop (somatostatin), so it rarely overshoots.

Evidence

Human-validated (former FDA drug Geref); very short half-life (~10–20 min) so consistent nightly dosing matters.

Approved drug

Somatropin (HGH) is approved for growth-hormone deficiency and tesamorelin (Egrifta) for HIV lipodystrophy. Secretagogues like this one are off-label.

References

researchdosing peptidedosages PubMed thepeptidereport Span 2000 Weissberger 1991

From the guide, page 88.